Psilocybin: A Potential Weapon Against Inflammation in Parkinson’s Disease
A groundbreaking new study published in JAMA Psychiatry on October 21, 2026, is offering scientists renewed optimism. It suggests that psychedelics may not only alter the mind but also combat disease-causing inflammation within the body. Researchers at the University of California, San Francisco (UCSF) have released some of the first human data indicating that psilocybin, the active compound in “magic mushrooms,” can significantly reduce biological markers of inflammation in individuals with Parkinson’s disease.
The pilot study monitored 12 Parkinson’s disease patients through two psilocybin sessions. The team used blood tests to measure five different inflammation-related signaling molecules before and after treatment. The participants exhibited significantly reduced inflammation levels post-sessions. Importantly, these changes were sustained a full month after the final dose. The researchers also monitored a blood marker of mitochondrial stress — the cellular energy factories — and noticed substantial improvements immediately after psilocybin administration.
Dr. Ellen Bradley, an associate professor of psychiatry at UCSF who co-led the analysis, described the findings as “an initial biological signal to investigate.” While experts acknowledge the study’s small size and lack of a control group, the results are stirring excitement far beyond neurology. Researchers believe these findings could potentially apply to depression, anxiety, and cardiovascular and inflammatory disorders in the future.
Source: NPR Health – October 21, 2026